NCT02584478
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
Phase: Phase 3
Role: Lead Sponsor
Start: Dec 31, 2015
Completion: Dec 31, 2024